UPJOHN's SECOND CEPHALOSPORIN FROM JAPAN IS CEFMETAZOLE
UPJOHN's SECOND CEPHALOSPORIN FROM JAPAN IS CEFMETAZOLE, licensed from Sankyo under an agreement announced on July 1. The agreement gives Upjohn exclusive U.S. marketing rights to the hospital product. Upjohn already has U.S. rights to a third-generation cephalosporin, cefpimizole sodium, from another Japanese firm, Aginomoto. Cefpimizole is currently in clinical trials in the U.S. In a press release announcing the Sankyo agreement, Upjohn said "cefmetazole is indicated for a broad range of infectious diseases and should become an important entry in Upjohn's line of hospital products." The firm added that it expects to submit an NDA for the product by 1988. Currently marketed in Japan, cefmetazole is reportedly that country's third largest selling hospital antibiotic. The cefmetazole agreement is the first license arrangement between Sankyo and Upjohn.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth